{"id":4468,"date":"2026-07-06T10:00:28","date_gmt":"2026-07-06T08:00:28","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=4468"},"modified":"2026-06-16T15:55:53","modified_gmt":"2026-06-16T13:55:53","slug":"repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/","title":{"rendered":"Repotrectinib in NTRK fusion-positive advanced solid tumors"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors &#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]New data from the phase 1\/ 2 trial TRIDENT-1, <a href=\"https:\/\/www.nature.com\/articles\/s41591-025-04079-7\" target=\"_blank\" rel=\"noopener\">recently published on Nature Medicine<\/a>, showed durable systemic and intracranial responses with generally low-grade adverse events in patients with NTRK fusion-positive advanced solid tumors.<\/p>\n<p>TRIDENT-1 is a registrational phase 1\/2 trial assessing repotrectinib, a next-generation ROS1\/TRK tyrosine kinase inhibitor, in adults with advanced solid tumors, including NTRK-positive disease. A total of 565 patients were enrolled and treated with at least one dose of repotrectinib for safety analysis; 120 patients with NTRK+ locally advanced or metastatic solid tumors who started treatment with repotrectinib at any dose were analyzed for efficacy. After a follow-up up to 25.7 months, the response rate was 59% in the tyrosine kinase inhibitors-naive population with a progression-free survival of 30.3 months; in patients pretreated with tyrosine kinase inhibitors, response rate was 48% and progression-free survival was 7.4 months; in pretreated patients with NTRK mutations response rate was 53%. Intracranial responses were observed in two of three tyrosine kinase inhibitors-naive patients and in four of six tyrosine kinase inhibitors-pretreated patients with measurable intracranial disease at baseline. Most treatment-related adverse events were low grade, the most common being dizziness (57%). \u00abRepotrectinib showed durable clinical activity in adult patients with NTRK-positive solid tumors, including in patients with previous tyrosine kinase inhibitors treatment, with or without intracranial disease\u00bb, authors say. \u00abThis evidence supports repotrectinib as a new treatment option for patients with NTRK-positive solid tumors. Looking forward, studies with longer follow-up and larger patient populations will help understand how response durability translates to overall survival as well as ascertain the ideal treatment sequence\u00bb.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;4482&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors &#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]New<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":4482,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-4468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-06T08:00:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1365\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Repotrectinib in NTRK fusion-positive advanced solid tumors\",\"datePublished\":\"2026-07-06T08:00:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/\"},\"wordCount\":327,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_06Jul26-scaled.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/\",\"name\":\"Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_06Jul26-scaled.jpg\",\"datePublished\":\"2026-07-06T08:00:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"A phase 1\\\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_06Jul26-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/Image_Nature_06Jul26-scaled.jpg\",\"width\":2560,\"height\":1365},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Repotrectinib in NTRK fusion-positive advanced solid tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna","description":"A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna","og_description":"A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2026-07-06T08:00:28+00:00","og_image":[{"width":2560,"height":1365,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Repotrectinib in NTRK fusion-positive advanced solid tumors","datePublished":"2026-07-06T08:00:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/"},"wordCount":327,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/","name":"Repotrectinib in NTRK fusion-positive advanced solid tumors - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg","datePublished":"2026-07-06T08:00:28+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"A phase 1\/2 trial shows promising antitumor activity for the next-generation tyrosine kinase inhibitor repotrectinib in NTRK fusion-positive advanced solid tumors","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2026\/07\/Image_Nature_06Jul26-scaled.jpg","width":2560,"height":1365},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/repotrectinib-in-ntrk-fusion-positive-advanced-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Repotrectinib in NTRK fusion-positive advanced solid tumors"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=4468"}],"version-history":[{"count":4,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4468\/revisions"}],"predecessor-version":[{"id":4498,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/4468\/revisions\/4498"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/4482"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=4468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=4468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=4468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}